Based on our in vitro results, we assessed the ability of this molecular classifier: BRAF MUT (any PI3K), or KRAS/NRAS MUT and PI3K WT to predict responsiveness to TAK-733 in 20 CRC PDXs (Figure 3). Here, NRAS is linked to colorectal carcinoma.